<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709540</url>
  </required_header>
  <id_info>
    <org_study_id>A011-02</org_study_id>
    <nct_id>NCT00709540</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalating study
      to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-011 in
      healthy postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of multiple, escalating doses of ACE-011 in healthy postmenopausal women.</measure>
    <time_frame>specified timepoints in the protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the pharmacokinetic (PK) parameters of multiple, escalating doses of ACE-011 administered subcutaneously and to determine the effect of ACE-011 on bone mineral density (BMD) and biochemical markers of bone formation and resorption.</measure>
    <time_frame>at specified timepoints in the protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects (8 active and 2 placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-011 or placebo</intervention_name>
    <description>multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is a postmenopausal woman, 45-85 years old (inclusive).

          2. Subject has had 12 months of spontaneous amenorrhea, OR 6 months of spontaneous
             amenorrhea with serum follicle stimulating hormone (FSH) levels &gt;40 IU/L OR is 6 weeks
             postsurgical bilateral oophorectomy with or without hysterectomy.

          3. Subject is taking at least 500 mg of calcium supplement and 400 IU of vitamin D daily
             and has been following this regimen for at least 4 weeks prior to the first dose of
             study drug administration.

          4. Subject has a body mass index (BMI) of â‰¥ 18.5 to &lt; 30.

          5. Subject must give written informed consent. If required by local law, candidates must
             also authorize the release and use of protected health information (PHI).

        Exclusion Criteria:

          1. Subject has a history of clinically significant major disease (as determined by the
             Investigator).

          2. Subject has a history of hyperparathyroidism, hypoparathyroidism, hypocalcemia,
             rheumatoid arthritis, myeloproliferative disorder, gout, Paget's disease of the bone,
             or osteomalacia.

          3. Subject has had a long bone fracture within the past 6 months prior to enrollment, or
             an osteoporosis-related fracture within the previous 2 years.

          4. Subject has a history of opportunistic infection, or has had a serious local or
             systemic infection within 3 months prior to screening.

          5. Subject has a history of severe allergic or anaphylactic reactions.

          6. Subject had major surgery within the previous 3 months.

          7. Subject has a history of drug or alcohol abuse, or tests positive in a drug and
             alcohol screen at screening or on Day 1 prior to dosing.

          8. Subject consumed any alcohol within 72 hours prior to dosing.

          9. Subject gave a blood donation (one unit or more) within 1 month prior to dosing, or
             plans to give a blood donation during the course of the study.

         10. Subject has taken any of the following bone active medications:

               -  Teriparatide at any time in their lifetime.

               -  Fluoride therapy for more than 3 months during the previous 2 years.

               -  Estrogen, androgen, anabolic steroids, corticosteroids (excluding inhaled,
                  topical or local injections for joint pain), calcitonin, or other bone active
                  drugs (e.g. selective estrogen receptor modulators) within the 4 months prior to
                  screening.

             Bisphosphonates:

               -  If treated for more than 6 months at any time in their lifetime.

               -  If treated for 3 to 6 months within 2 years of screening.

               -  If treated for less than 3 months within 6 months of screening.

         11. Subjects with chronic stable diseases including migraines, hypertension, hyperthyroid
             disorder, hypothyroid disorder, gastroesophageal reflux disease, or mild
             depression/anxiety will be excluded unless the investigator does not have safety or
             compliance concerns at study entry.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Ababa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2008</study_first_submitted>
  <study_first_submitted_qc>July 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <last_update_submitted>December 8, 2008</last_update_submitted>
  <last_update_submitted_qc>December 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matthew L Sherman MD</name_title>
    <organization>Acceleron Pharma Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

